1 Volmink J, Gamer P. Directly observed therapy for treating tuberculosis [J].Cochrane Database Syst Rev 2003,1：CD003343
2 Thomas C. A literature review of the problems of delayed presentation for treatment and non-completion of treatment for tuberculosis in leas devel-oped countries and ways of addressing these problems using particular im-plementations of the DOTS strategy [J].I Manag Med, 2003,16：371-400
3 Ahsan F, Rivas IP, Khan MA. AITS Targeting to macrophages: role of physicochemical properties of particulate ciriers-liposomes and micro-spheres-on the phagocytosis by macrophages [J].J. Controlled Release 2002,79:29-40
4 Wu XS. Preparationt characterization, and drug delivery applications of microspheres based on biodegradable lactic/glycolic acid polymers. Ency-clopedic handbook of biomaterials and bioengineering[J]. New York：Mar-cel Dekker, 1995,p. 1151-200
5 Ain Q, Sharma S, Carg SK,et al. Role of poly[DL-lactic-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s)[J].lnt J Pharm,2002,239:37-46
6 Barrow ELW, Winchester GA, Staas JK，et al. Use of microsphere technol-ogy for sustained and targeted delivery of rifampin to Mycobacterium tu-berc ulosts-in fected macrophages [J] . Antimicrob Agents Chemother,1998,42:2682-2689
7 Barrow WW, Barrow EL, Quenelle DC,et al. inventors； Southern Research Institute，assignee. Compositions anii methods for treating intracellular in-fections[J]. USA patent,2001
8 Bo6ela AA. El-Sayed MM, Mahmoud MI. Preparation of targeted isoniazid microsphereat[J].Boll Chim Farm, 1998,137:77-81
9 Dutt M, Khuller GK. Poly( DL-lactide-co-glycolide) microparticlcs as car-riers for anti mycobacterial drugrifampicin [J]. Indian J Exp Biol，2000,38:887-894
10 Dutt M, Khuller GKUposomes and PLG microparticles as sustained re-lease anlitubereular drug carriers-an in vitro-in vivo study [J]. Internat J Antimicrob Agents,2001,18:245-252
11 Dutt M t Khuller GK. Therapeutic efficacy of poly(DL-lactide-co-glycol-ide)-encapsulated antitubercular drugs against Mycohacterium tuberculo-sis infection induced in mice [J]. Antimicrob Agents Chemother, 2001,45:363-366
12 Dutt M, Khuller GK. Chemotherapy of Mycobacterium tuberculosis infec-tions in mice with a combination of isoniazid and rifampicin entrapped in poly( DL-lactide-co-glyqolide)micro-paticles[J]. J Antimicrob Chemoth-er 2001,47:829-835
13 Dutt M, Khuller CK. Sustained release of isonia7id from a single in-jectable dose of poly( DL-lactidc-co-glycolide) microparticles as a thera-peutic approach towards luberculosis[J]. Intemat J Antimicrob Agents,2001,17:115-122
14 O'Hara P, Hickey AJ. Respirable PLGA microspheres containing ri-fampicin for the treatment of tuberculosis： manufacture and chamcteriza-tion[J]. Pharm Res，2000,17:955-961
15 Quenelle DC,Staas JK, Winchester GA, et al. Efficacy of microencapsu-laled rifampin in Mycobacterium luberculosis-infected mice[J]. Antimi-crob Agents Chemother 11999,43；1141-1151
16 Quenelle DC, Winchester GA，Staas JK, et al-Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isonia2id[J]. Antimicrob Agents Chemother,2001,45:1637-1644
17 Sharma R, Saxena D, Dwivedi AK, et al. Inhalable microparticles con-taining drugcombinations to atrget alveolar macrophages for treatment of pulmonary tuberculosis[J] . Pharm Res,2001,18:1405-1410
18 Suarez S.O'Hara P,Kazantseva M,et al.Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis： screening in an infectious disease modle[J] . Pharrn Res,2001 ,18:1315-1319
19 Suarez S,0'Hara P, Kazantseva M,el al. Airways delivery of rifampicin microparticles for the treatment of tuberculosis [J]. J Antimicrob Chemother, 2001,48:431-434
20 UI-Ain Q, Sharma S, Khuller GK. Chemotherapeutic potential of orally administered poly (lactide-do-glycolide) microparticles containing isoni-azid t rifampin, and pyrazinamide against experimental tuberculosis [J].Antimicrob Agents Chemother, 2003 f 47 ： 3005-3007
21 UI-Ain Q，Sharma S，Khuller GK, et al. Alginate-based oral drug delivery system for tuberculosis： pharmacokinetics and therapeutic effects[J] . J Antimicrob Chemother,2003,51 ：931 -938
22 Pandey Rajesh , Khuller GK. Chemotherapeutic potential of alginate-chi-tosan microspheres as anti-tubercular drug carriers [J]. J Antimicrob Chemother, 2004,53:635-640
23 Zhou H, Zhang Y, Biggs DL,et al. Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages [J]. J Control Release,2005,107(2) :288-299
24 Gangadharam PR J, Kailasam S，Srinivasan S, et al. Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymere[J].J Antimicron Chemother,1994,33:265-271
25 Hsu YY, Gresser JD，Trantolo DJ, et al. In vitro controlled release of iso-niazid from poly (lactide-co-glycolide) matrices [J]. J Control Release,1994,31:223-228
26 Kailasam S，Danaluzzi D, Cangadhann PRJ. Maintenance of therapeuti-cally active levels of isoniazid for prolonged periods in rabbits after a sin-gle implant of biodegradable polymer[J] .Tuber Lung Dis, 1994,75:361-365
27 Quenelle DC，Barrow EW，Winchesler GA,et al. Sustained release char-acteristics of rifampin-loaded microsphere formulations in ncHi-human primates[J]. Drug Deliv,2004,11(4) :239-246
|
京公网安备11010202007215号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
